Lilly’s Tirzepatide Sheds Lean Muscle Harder than Novo’s Semaglutide, Study Suggests

Why It Matters

Greater lean‑mass loss could affect long‑term health and reshape prescribing preferences between two market‑leading obesity drugs, impacting both patient outcomes and competitive dynamics.

Key Takeaways

• Tirzepatide leads to greater total weight loss than semaglutide
• Study shows tirzepatide also causes higher lean muscle loss
• Lean mass reduction may affect long‑term health outcomes
• Findings could influence clinicians’ drug choice for obesity management
• Novo’s semaglutide retains more muscle while still promoting weight loss

Pulse Analysis

Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide have reshaped the obesity‑treatment landscape in the past few years. Both are injectable incretin mimetics, but tirzepatide uniquely activates both GLP‑1 and GIP receptors, delivering average weight reductions of 15‑20 % in phase III trials, compared with roughly 12‑15 % for semaglutide. The drugs have quickly become blockbuster candidates, generating billions in annual sales and prompting insurers to expand coverage. Their efficacy has spurred a wave of off‑label use among patients seeking rapid weight loss.

A newly released, yet‑to‑be‑peer‑reviewed analysis of head‑to‑head trials suggests that tirzepatide’s superior weight loss may come at a cost: a proportionally larger decline in lean body mass. Researchers measured fat‑free mass using dual‑energy X‑ray absorptiometry and found tirzepatide participants lost up to 30 % more muscle than those on semaglutide, despite similar calorie deficits. Loss of muscle tissue can impair metabolic rate, reduce functional capacity, and increase frailty, especially in older adults or those with chronic disease.

The findings could tilt prescribing habits toward semaglutide for patients where muscle preservation is paramount, such as the elderly or individuals engaged in strength training. From a commercial perspective, the data gives Novo Nordisk a potential differentiator in a market where tirzepatide is already gaining traction. Regulators may also request additional safety endpoints in future label updates. Ultimately, clinicians will need to balance the trade‑off between maximal weight loss and lean‑mass retention, and further long‑term studies are essential to clarify health outcomes.